CMS reinstates enforcement discretion under CLIA for certain SARS-CoV-2 tests
During the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services will continue to exercise enforcement discretion under the Clinical Laboratory Improvement Amendments to allow providers to test asymptomatic individuals using certain point-of-care SARS-CoV-2 tests authorized for symptomatic individuals, the Centers for Medicare & Medicaid Services announced Friday. The decision rescinds a Sept. 26 memorandum that ended the 2020 enforcement discretion policy.
Related News Articles
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…